APPENDIX TABLE 8.

EFFECTS OF TREATMENT ON FASTING BLOOD GLUCOSE, HbA1c AND QUICK INDEX

			BASELINE			6 MONTHS				12 MONTHS
			Mean (SD)	minimum-maximum		Mean Change *	95% CI	P Value MK-677 vs. Placebo †		Mean Change *	95% CI	P Value MK-677 vs. Placebo †
FBG, HbA1c, Quicki Index
FBG, mmol/L	Placebo		5.4 (0.4)	4.6-6.3		0.1	-0.2 - 0.3			0.0	-0.3 - 0.2
	MK-677		5.5 (0.4)	4.7-6.4		0.2	0.1 - 0.4	0.27		0.3	0.1 - 0.4	0.015
FBG, mg/dL	Placebo		98 (8)	83-113		1	-3 - 6			-1	-5 - 3
	MK-677		99 (7)	84-115		4	1 - 8	0.27		5	2 - 7	0.015
HbA1c, %	Placebo		5.4 (0.4)	4.7-6.4		-0.2	-0.3 - 0.0			-0.1	-0.2 - 0.1
	MK-677		5.4 (0.3)	4.7-6.0		0.2	0.0 - 0.3	0.001		0.2	0.1 - 0.3	0.002
Quicki Index	Placebo	N=21	0.36 (0.03)	0.33-0.41	N=21	0.004	-0.004-0.012		N=21	0.005	-0.003-0.013
	MK-677	N=41	0.36 (0.03)	0.27-0.43	N=41	-0.012	-0.018 to -0.006	<0.001	N=41	-0.013	-0.019 to -0.008	<0.001

Baseline data presented are the arithmetic mean (SD) and the minimum and maximum values; Placebo (N=22) and MK-677 (N=43) unless otherwise indicated.

^*Mean change (arithmetic difference) from baseline with 95% confidence limits at 6 months and at 12 months

^†P values are for the pivotal comparisons between the two groups at 6 months and at 12 months.

Quicki Index - estimate of insulin sensitivity from fasting glucose and insulin

Abbreviations: FBG = fasting blood glucose; HbA1C = hemoglobin A1c